NCT07111247View on ClinicalTrials.gov

Insights in Endocervical Mucus Secretion

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Cervical Mucus
Interventions
DRUG

Gonadotropin Releasing Hormone Antagonists Relugolix

Gonadotropin releasing hormone antagonist (gnRH) taken for 10 days starting during the midluteal phase.

Trial Locations (1)

97239

Oregon Health & Science University, Portland

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Oregon Health and Science University

OTHER